SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549

                                    FORM 10-Q


                 QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


                    For the Quarter Ended September 26, 1999

                         Commission File Number 1-12767


                               CHEMFAB CORPORATION
             (Exact name of registrant as specified in its charter)


                      Delaware                           03-0221503
         (State or other jurisdiction of              (I.R.S. Employer
         incorporation or organization)               Identification No.)

             701 Daniel Webster Highway
             Merrimack, New Hampshire                  03054
             (Address of principal executive office)   (Zip Code)


             Registrant's telephone number including
             area code:                                (603) 424-9000


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed  by  Section  13 or 15 (d) of the  Securities  Exchange  Act of 1934
during the preceding 12 months (or for such shorter  period that the  registrant
was  required  to file such  reports),  and (2) has been  subject to such filing
requirements for the past 90 days.

                                             YES   X    NO_____.


Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.


                     Class                    Outstanding at October 29, 1999
         Common Stock, $0.10 par value        7,685,756 Shares

<PAGE>

                               CHEMFAB CORPORATION
                                      INDEX


                                                                       Page No.

Part I - Financial Information:

   Item 1 -       Financial Statements

                           Consolidated Balance Sheets at September       3
                           26, 1999 and June 30, 1999

                           Consolidated Statements of Income for          5
                           the Three Months Ended September 26,
                           1999 and September 27, 1998

                           Consolidated Statements of Cash Flows          6
                           for the Three Months Ended September
                           26, 1999 and September 27, 1998

                           Notes to Consolidated Financial Statements     7

   Item 2 -       Management's Discussion and Analysis of                10
                  ---------------------------------------
                  Financial Condition and Results of Operations
                  ---------------------------------------------

Part II - Other Information:

   Item 6(a) - Exhibits                                                  13
               --------

   Item 6(b) - Reports on Form 8-K                                       13
               -------------------


   Signatures                                                            14

<PAGE>


                               CHEMFAB CORPORATION
============================================================================

                           CONSOLIDATED BALANCE SHEETS
============================================================================

                     (in thousands except par value amounts)


                                                    September 26,      June 30,
                                                         1999           1999
                                                     (Unaudited)

Current assets:
    Cash and cash equivalents                          $   6,450    $    4,783
    Receivables:
       Trade                                              24,374        25,020
       Other                                                  62            92
     Inventories                                          21,691        19,649
     Costs and estimated earnings in excess of
       billings on uncompleted contracts                   1,593           958
    Prepaid expenses, and other current assets             3,379         3,266
    Deferred tax assets                                    1,248         1,248
                                                       ---------    ----------
       Total current assets                               58,797        55,016

Property, plant and equipment, at cost                    60,868        59,418
    Less: accumulated depreciation                      (30,671)       (29,466)
                                                       ----------   -----------

   Property, plant and equipment, net                     30,197        29,952

Goodwill, net                                             20,544        19,297
Other assets                                               2,159         2,103

                                                       ----------   -----------

          Total assets                                 $ 111,697    $  106,368
                                                       ==========   ===========

See accompanying Notes to Consolidated Financial Statements.   (page 1 of 2)

<PAGE>

===============================================================================
                               CHEMFAB CORPORATION
===============================================================================
                           CONSOLIDATED BALANCE SHEETS
===============================================================================
                     (in thousands except par value amounts)
===============================================================================


                                                      September 26,    June 30,
                                                          1999            1999
                                                       (Unaudited)
Current liabilities:
    Accounts payable and accrued
         Expenses                                      $   15,935    $   14,974
    Short term borrowings                                  12,820        11,028
   Accrued income taxes                                     2,440         1,209
   Billings in excess of costs and
         estimated earnings on
         uncompleted contracts                                123           250
                                                       -----------   ----------

       Total current liabilities                           31,318        27,461
                                                       -----------   ----------


Deferred tax liabilities                                    2,051         2,051

Shareholders' equity:
    Preferred stock, par value $0.50:
       authorized - 1,000 shares,
       none issued                                              -             -
    Common stock, par value $0.10:
       authorized - 15,000 shares;
       issued 8,852 shares at September 26, 1999              885           883
       and 8,828 shares at June 30, 1999
    Additional paid-in capital                             27,081        26,829
    Retained earnings                                      72,122        69,972
    Treasury stock, at cost
        (1,196  shares at September 26, 1999
         and 1,091 at June 30, 1999)                      (20,800)      (19,012)

         Accumulated other comprehensive income              (960)       (1,816)
                                                       ------------   ---------

       Total shareholders' equity                          78,328        76,856
                                                       ------------   ---------

          Total liabilities and shareholders'          $  111,697     $ 106,368
                                                       ============   =========

See accompanying Notes to Consolidated Financial Statements. (page 2 of 2)

<PAGE>

===============================================================================
                               CHEMFAB CORPORATION
===============================================================================
                        CONSOLIDATED STATEMENTS OF INCOME
===============================================================================
                                   (Unaudited)
                     (in thousands except par value amount)
===============================================================================

                                                  Three Months Ended
                                             ================================

                                             Sept. 26, 1999    Sept. 27, 1998

Net sales                                    $      26,038     $    25,233
Cost of sales                                       16,722          16,796
                                             --------------    --------------

Gross profit                                         9,316           8,437
Selling, general and
   administrative expenses                           5,301           4,254
Research and development                               712             860
Other expense (income)                                 153            (124)
Interest expense (income), net                          79            (103)
                                             --------------    ---------------

Income before income taxes                           3,071           3,550

Provision for income taxes                             921           1,157
                                             --------------    ----------------

Net income                                   $       2,150     $     2,393
                                             ===============   ================

Earnings per share:

   - Basic                                           $0.28           $0.31
   - Diluted                                         $0.27           $0.30

Weighted average common share outstanding:

   - Basic                                           7,702           7,816
   - Diluted                                         7,864           8,092


See accompanying Notes to Consolidated Financial Statements.

<PAGE>

-------------------------------------------------------------------------------
                               CHEMFAB CORPORATION
-------------------------------------------------------------------------------
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------------------------------------------------
                                   (Unaudited)
                                 (in thousands)
-------------------------------------------------------------------------------

                                                           Three Months Ended
                                                         -----------------------
                                                         Sept. 26,     Sept. 27,
                                                           1999          1998
                                                         -----------------------


Cash flows from operating activities:

   Net income                                            $   2,150  $     2,393
   Adjustments to reconcile net income to net
     cash provided by operations:
        Depreciation                                         1,069          937
        Amortization                                           540          401
        Special Charges, non cash portion                     (630)           0
        Change in working capital:
           Receivables                                       1,261        2,619
           Inventories                                      (1,357)      (1,324)
           Costs and estimated earnings in excess
             of billings on uncompleted contracts, net        (763)        (531)
           Prepaid expenses and other current assets          (229)        (251)
           Other assets                                       (513)        (531)
           Accounts payable and accrued expenses               979          (37)
           Accrued income taxes                              1,171          588
           Deferred tax assets and liabilities                   0           (1)
                                                         ----------  -----------

           Total adjustments                                 1,528        1,870
                                                         ----------  -----------

           Net cash provided by operations                   3,678        4,263

   Cash flows from investing activities:
        Acquisitions, net of cash acquired                  (1,236)      (6,123)
        Capital expenditures (net)                          (1,122)      (4,933)
                                                         ----------  -----------

           Net cash used in investing activities            (2,358)     (11,056)

   Cash flows from financing activities:
        Short-term borrowings (repayments), net              1,739            0
        Proceeds from exercise of stock options                254          108
        Purchase of treasury shares                         (1,788)           0
                                                         ----------  -----------

   Effect of exchange rate changes on cash                     142           54
                                                         ----------  -----------

   Net increase/(decrease) in cash and cash equivalents      1,667       (6,631)

   Cash and cash equivalents at beginning of year            4,783       11,099



   Cash and cash equivalents at end of period            $   6,450   $    4,468
                                                         =========   ===========

  Interest paid                                          $     158   $        0
  Income taxes paid                                      $      52   $      677

 See accompanying Notes to Consolidated Financial Statements.

<PAGE>

                               CHEMFAB CORPORATION
                   Notes To Consolidated Financial Statements.
                               September 26, 1999
                                   (Unaudited)

Note 1 -  Significant Accounting Policies

          Principles of Consolidation:

          The  consolidated  financial  statements of Chemfab  Corporation  (the
          Company)  included in this report reflect all adjustments  (consisting
          of  only  normally  recurring  accruals)  which,  in  the  opinion  of
          management,  are necessary for a fair presentation of the consolidated
          financial  position  at  September  26, 1999 and June 30, 1999 and the
          consolidated  statements of income and cash flows for the three months
          ended September 26, 1999 and September 27, 1998. The unaudited results
          of operations  for the interim  periods  reported are not  necessarily
          indicative of results to be expected for the year.

          Certain  notes and other  information  have been  condensed or omitted
          from these interim financial  statements.  The statements,  therefore,
          should  be  read  in  conjunction  with  the  consolidated   financial
          statements  and related  notes  included  in the  Chemfab  Corporation
          Annual  Report on Form 10-K for the year ended June 30, 1999 (file no.
          1-12767).

Note 2 -  Acquisitions

          On July 16, 1999,  the Company  completed  the purchase of the capital
          stock of Holding  Christian  Cases S.A.  (HCC) for  $1,236,000  in net
          cash, including  associated  transaction costs. The purchase agreement
          also  requires  the payment of  approximately  $100,000 in each of the
          following two years for a non-compete  agreement.  The acquisition was
          accounted for using the purchase  method of  accounting.  Prior to the
          acquisition,  the main business of HCC and its subsidiaries was in the
          fabrication  and  distribution  of PTFE  composite  products in France
          principally  purchased  from  Chemfab.  This  business  is expected to
          continue.  The  acquisition  of HCC  resulted  in the  recognition  of
          goodwill of  approximately  $858,000  which will be amortized  over 15
          years.

          In June  1999,  the  Company  entered  into an  agreement  to  acquire
          UroQuest  Medical  Corporation  (Uroquest).  The Company is scheduled,
          subject to the completion of standard  transaction  contingencies,  to
          consummate the acquisition of UroQuest in the second quarter of fiscal
          2000. (See Liquidity and Capital Resources, page 11.)

Note 3 -  Debt:

          In September 1999, the Company has amended its  $20,000,000  revolving
          credit agreement with two commercial  banks, one based in the U.S. and
          the other in Ireland.  Under the terms of the  agreement,  the Company
          has available a $20,000,000  unsecured  credit facility until December
          31, 1999.  The loan  agreement  requires that any balance  outstanding
          will at  December  31,  1999,  convert  into a  four-year  loan with a
          five-year  amortization  schedule  and a lump sum payment due December
          31, 2003. In connection with the planned acquisition of UroQuest,  the
          Company is  currently  negotiating  to replace  its'  existing  credit
          facility.

<PAGE>

Note 4 -  Inventories:

          Inventories consisted of the following:

                             Sept. 26, 1999            June 30,1999
                                           (in thousands)
          Finished Goods          $ 7,152                   7,541
          Work in Process           7,519                   6,160
          Raw Materials             7,020                   5,948
                                  -------                 -------
                                  $21,691                 $19,649
                                  =======                 =======

Note 5 -  Comprehensive Income:
          The components of comprehensive income were as follows:

                             Sept. 26, 1999            Sept. 27, 1998
                                           (in thousands)
          Net income              $ 2,150                 $ 2,393
          Foreign currency            856                     523
          translation adjustments
                                  -------                 -------
          Comprehensive income    $ 3,006                 $ 2,916
                                  =======                 =======

Note 6 -  Segment Reporting:

          The Company adopted  Statement of Financial  Accounting  Standards No.
          131 (SFAS No. 131),  "Disclosures  about Segments of an Enterprise and
          Related   Information"  in  fiscal  1999.  SFAS  No.  131  establishes
          standards  for the way  the  Company  reports  information  about  its
          operating segments. The quarterly information required by SFAS No. 131
          is presented below:

                           Americas     European      Other   Consolidation
                           Business     Business
                              Group        Group

Three months ended Sept. 26, 1999
Revenue from
        external customers   $15,284     $ 7,794     $2,960     $ 26,038
Intersegment sales               729         176          0          905
Operating income 1,039         1,039         194        456        1,689
Identifiable assets           59,699      47,981      4,343      112,023


Three months ended Sept. 27, 1998
Revenue from
        external customers   $16,148     $ 6,429     $2,656     $ 25,233
Intersegment sales               983         273          0        1,256
Operating income 1,364         1,364         316        297        1,977
Identifiable assets           55,505      34,570      4,402       94,477

<PAGE>

The  following  is the  reconciliation  from Segment  Reporting to  Consolidated
Results:

                                  September 26, 1999     September 27, 1998

Revenue
Total external revenues
        for reportable segments         $23,078                 $22,577
Intersegment revenues for
        reportable segments                 905                   1,256
Other                                     2,960                   2,656
Elimination of Intersegment
        Revenue  (905)                     (905)                 (1,256)

Total consolidated revenues             $26,038                 $25,233

Operating profit
Total profit for
        reportable segment               $1,689                  $1,977
Interest charged on
        capital employed                  1,470                   1,470
Net interest (expense) income               (88)                    103

Income before income taxes               $3,071                  $3,550


Note 7  - Commitments and Contingencies:

          Various  lawsuits and claims are pending or have been  asserted by and
          against the Company,  including  matters  previously  disclosed by the
          Company in its Form 10-K for the year ended  June 30,  1999.  Although
          the outcome of such matters  cannot be predicted  with  certainty  and
          some lawsuits or claims may be disposed of unfavorably to the Company,
          management   believes  that  the  disposition  of  its  current  legal
          proceedings,  to the extent not covered by insurance,  will not have a
          material  adverse  effect on the  Company's  financial  condition  and
          results of operations.

<PAGE>

ITEM 2                 Management's Discussion and Analysis of
                  Financial Condition and Results of Operations
                      Three Months Ended September 26, 1999

Net Sales

The Company's  consolidated  net sales for the three months ended  September 26,
1999,  the first  quarter of fiscal 2000,  increased  3.2% to  $26,038,000  from
$25,233,000 in the same quarter last year. Shipments of the Company's Engineered
Products worldwide increased 14% over the year earlier period while shipments of
architectural  products  decreased 35%.  Measured in constant  foreign  currency
rates, consolidated revenue would have increased by 3.5%.

The Americas Business segment sales (which include all Engineered  Product sales
from the Company's U.S.  manufacturing  plants into principal geographic markets
in the Americas  and  Architectural  Product  sales  worldwide)  decreased 5% to
$15,284,000 from $16,148,000 for the same quarter last year. This sales decrease
resulted from low Architectural  Product sales in the quarter which declined 35%
compared with the same period last year. The Architectural decline was offset by
10% growth in Engineered  Product sales. It is expected that revenues from sales
of  Engineered  Products  and  Architectural  Products,  particularly  into  the
Americas, will remain relatively solid through the end of the fiscal year.

The European Business segment sales (which include all Engineered  Product sales
from the Company's European  manufacturing plants;  principal geographic markets
are Europe and Africa)  increased 21% to $7,794,000  from $6,429,000 in the same
quarter last year.  Acquisitions  completed last year contributed  $1,833,000 of
the increased  revenue in the European  Business  segment.  Sales growth for the
balance  of  the   European   Business   segment  is  expected  to  continue  at
approximately the same rate for the remainder of the fiscal year.

Sales in our other Business segment, which includes all Engineered Product sales
to the Far East and sales from the Company's High Performance Elastomer Division
(HPE) combined,  increased 11% to $2,960,000 from $2,656,000 in the same quarter
last year.  This  increase is due to a  strengthening  of the economy in certain
Asian countries and to expansion of HPE's domestic and European markets. Revenue
growth in the Asia Pacific Business segment and the High Performance Division is
expected to continue at  approximately  this same rate through the  remainder of
the fiscal year.

Gross Profit Margins

Gross profit  margins as a percentage  of  consolidated  net sales  increased to
35.8% for the  quarter,  up from 33.4% for the first  quarter of last year.  The
increase  is due to a  greater  proportion  of high  margin  products  and lower
Architectural  sales,  and the  incremental  gross  profits  from  our  European
fabrication acquisitions.

Selling, Administrative, Research and Development Expenses

Selling,  general and  administrative  expenses increased 25% to $5,301,000 from
$4,254,000  in the same  quarter  last  year.  Increased  selling,  general  and
administration  expenditures  resulted from additional  expenses relating to the
acquisitions  completed in the last fiscal year, as well as normal  increases in
salaries  and other costs.  Selling,  general and  administrative  expenses as a
percentage of sales were 20%, up from the first  quarter of last year.  Research
and  development  expenses  were  $712,000  compared  to last  year's  level  of
$860,000.  This level of spending,  at  approximately  3% of total revenues,  is
consistent with recent,  as well as planned,  levels of research and development
spending.

<PAGE>

Interest Expense, Net

The Company had net interest  expense of $79,000 for the quarter compared to net
interest income of $103,000 for the same quarter last year,  largely as a result
of a lower average cash balance and borrowings made to fund acquisitions.

                         Liquidity and Capital Resources

During the quarter ended September 26, 1999, the Company generated $3,678,000 of
cash from  operations,  which was down from the same  quarter of the prior year.
During this same period, the Company invested $1,122,000 in property,  plant and
equipment  additions and expended  $1,788,000  for the  acquisition  of treasury
shares.  The Company  also  received  $254,000 in cash  proceeds and related tax
benefits from the exercise of stock options during this period.

Working capital  decreased to $27,479,000  from $27,555,000 at the end of fiscal
1999. As of September 26, 1999, the Company had an aggregated  line of credit of
approximately   $20,000,000.   As  of  September  26,  1999,   the  Company  had
approximately $4,369,000 available under this facility. Management believes that
the combination of cash on hand, cash expected to be generated from  operations,
and available credit  facilities will be adequate to finance  operations  during
fiscal 2000 and to deal with any liabilities or contingencies  described in Note
7 to the Consolidated Financial Statements. The Company is scheduled, subject to
the  completion  of  standard  transaction  contingencies,   to  consummate  the
implementation  of a new $60,000,000  unsecured  credit loan facility during the
second  quarter  of  fiscal  2000.  The new  facility  will be used to fund  the
UroQuest acquisition and to replace the existing credit loan facility.

                                    Year 2000

     In 1993, the Company began its program to prepare for the Year 2000 issues.
The Company has made steady  progress  since then in  addressing  this  computer
programming  challenge.  The  Company is  continuing  to analyze  operations  to
determine and implement the procedures  necessary to ensure timely and effective
Year 2000 compliance. The Company has generally completed the identification and
assessment phase of its Year 2000 program.  The Company believes that all of its
major  information  management  and  operations  systems are currently Year 2000
compliant.

     The Company has spent approximately $1,525,000 to become Year 2000 capable,
and does not expect any additional material out-of pocket expenses to become Y2K
compliant.

     The  Company has also  identified  and been in  communication  with its key
third party  vendors and  suppliers,  both to determine  the extent to which the
Company might be  vulnerable to such parties'  failure to resolve their own Year
2000  issues,  and  to  plan  for  the  satisfactory   resolution  of  any  such
contingencies.  Where  practicable,  the  Company  will  continue  to assess and
attempt to mitigate its risks with respect to the failure of its suppliers to be
Year  2000  ready.  The  Company  has  surveyed  its key  customers,  and  where
appropriate,  made  plans in light of their  state of Year 2000  readiness.  One
contingency plan, for example, provides for the Company to continue to serve its
customers through redundant manual order-entry and other systems.

<PAGE>

     The  Company  has had  continuing  discussions  with  its key  vendors  and
customers about  contingency plans for operational,  systems and  infrastructure
failures resulting from the Year 2000 problem.

     While no assurance  can be given,  the Company does not  anticipate at this
time  that the Year 2000  problem  will have a  material  adverse  impact on the
Company's business, financial condition or results of operation. In the event of
a business interruption as a result of a Year 2000 problem at one facility,  the
Company plans to shift  necessary  production to the extent  possible to utilize
capacity at other sites. Similarly,  most of the Company's vendors and customers
have more than one production site from, or to, which orders can be fulfilled or
sent.  In the worst  case,  however,  there  could be a  temporary  shutdown  of
production  and an  associated  slippage or even loss of revenues (to the extent
not made up in subsequent time periods).

                           Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in
this Form 10-Q are forward-looking  statements within the meaning of the Private
Securities  Litigation  Reform Act of 1995, as amended.  Investors are cautioned
that forward-looking statements are inherently uncertain. Actual performance and
results may differ  materially  from those projected or suggested due to certain
risks  and  uncertainties,  including  the  integration,  transition,  and where
appropriate,  consolidation of the UroQuest  transaction and other  acquisitions
already  completed.   Additional   information   concerning  certain  risks  and
uncertainties  that could cause actual results to differ  materially  from those
projected or suggested is contained in the Company's  Annual Report on Form 10-K
for the fiscal year ended June 30, 1999 which has been filed with the Securities
and  Exchange  Commission.   The  forward-looking  statements  contained  herein
represent the Company's  judgment as of the date of this filing, and the Company
cautions readers not to place undue reliance on such statements.

<PAGE>

                           Part II - Other Information

ITEM 3 - Legal Proceedings

See the information  under the caption "Note 7 - Commitments and  Contingencies"
in Notes to Consolidated Financial Statements of this Form 10Q.

ITEM 6 - Exhibits and Reports on Form 8-K

         6(a)       Exhibits

                    (27)     Financial Data Schedule

                    10b(10)  Amendment No. 1 to $20,000,000  Credit Agreement by
                             by  and  between  Chemfab  Corporation  as borrower
                             and The First National Bank of Boston  and The Bank
                             of Ireland as lenders.

         6(b)       Reports on Form 8-K
                    None.

<PAGE>

                               CHEMFAB CORPORATION

                                   SIGNATURES

PURSUANT  TO THE  REQUIREMENTS  OF THE  SECURITIES  EXCHANGE  ACT OF  1934,  THE
REGISTRANT  HAS DULY  CAUSED  THIS  REPORT  TO BE  SIGNED  ON ITS  BEHALF BY THE
UNDERSIGNED THEREUNTO DULY AUTHORIZED.


                CHEMFAB CORPORATION
                (Registrant)




                By:/S/ John W. Verbicky
                President, Chief Executive Officer and Director




                By:/S/Moosa E. Moosa
                Moosa E. Moosa
                Vice President - Finance, Treasurer and Chief Financial Officer
                (Principal Financial Officer)




                By:/S/ Hilary A. Arwine
                Hilary A. Arwine
                Corporate Controller
                (Principal Accounting Officer)






Date: November 10, 1999

<PAGE>

                               CHEMFAB CORPORATION

                                   SIGNATURES

PURSUANT  TO THE  REQUIREMENTS  OF THE  SECURITIES  EXCHANGE  ACT OF  1934,  THE
REGISTRANT  HAS DULY  CAUSED  THIS  REPORT  TO BE  SIGNED  ON ITS  BEHALF BY THE
UNDERSIGNED THEREUNTO DULY AUTHORIZED.


                CHEMFAB CORPORATION
                (Registrant)




                By:
                John W. Verbicky
                President, Chief Executive Officer and Director



                By:
                Moosa E. Moosa
                Vice President - Finance, Treasurer and Chief Financial Officer
                (Principal Financial Officer)




                By:
                Hilary A. Arwine
                Corporate Controller
                (Principal Accounting Officer)



Date: November 10, 1999